Arbutus Biopharma (NASDAQ:ABUS) Earns Buy Rating from HC Wainwright

Arbutus Biopharma (NASDAQ:ABUS - Get Free Report)'s stock had its "buy" rating restated by stock analysts at HC Wainwright in a report issued on Thursday, MarketBeat Ratings reports. They presently have a $5.00 price target on the biopharmaceutical company's stock. HC Wainwright's target price points to a potential upside of 49.70% from the company's current price.

ABUS has been the subject of a number of other research reports. Chardan Capital reaffirmed a "buy" rating and issued a $4.00 price objective on shares of Arbutus Biopharma in a report on Wednesday. JMP Securities reaffirmed a "market outperform" rating and issued a $4.00 price objective on shares of Arbutus Biopharma in a report on Thursday, April 4th.

Arbutus Biopharma Stock Performance

NASDAQ ABUS traded down $0.29 on Thursday, reaching $3.34. 1,624,135 shares of the company's stock traded hands, compared to its average volume of 1,161,649. The firm has a market cap of $630.32 million, a price-to-earnings ratio of -7.59 and a beta of 1.98. The stock has a 50 day moving average price of $2.97 and a 200-day moving average price of $2.62. Arbutus Biopharma has a fifty-two week low of $1.69 and a fifty-two week high of $3.64.

Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.10). The company had revenue of $1.53 million during the quarter, compared to the consensus estimate of $2.16 million. Arbutus Biopharma had a negative net margin of 572.81% and a negative return on equity of 62.68%. As a group, equities research analysts anticipate that Arbutus Biopharma will post -0.39 EPS for the current fiscal year.

Institutional Trading of Arbutus Biopharma

Institutional investors and hedge funds have recently modified their holdings of the stock. Walleye Trading LLC purchased a new stake in shares of Arbutus Biopharma during the first quarter worth about $36,000. China Universal Asset Management Co. Ltd. grew its stake in Arbutus Biopharma by 351.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 19,400 shares of the biopharmaceutical company's stock valued at $49,000 after acquiring an additional 15,104 shares in the last quarter. PFG Investments LLC purchased a new stake in Arbutus Biopharma during the 1st quarter valued at about $50,000. Premier Path Wealth Partners LLC purchased a new stake in Arbutus Biopharma during the 4th quarter valued at about $56,000. Finally, Price T Rowe Associates Inc. MD grew its stake in Arbutus Biopharma by 22.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 36,388 shares of the biopharmaceutical company's stock valued at $94,000 after acquiring an additional 6,649 shares in the last quarter. Hedge funds and other institutional investors own 43.79% of the company's stock.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.